Improved Oral Health for Head and Neck Cancer Survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter randomized controlled trial tests whether an ongoing oral care program, delivered quarterly for three years starting six months after cancer treatment, can prevent or lessen late oral side effects in head and neck cancer survivors. The study compares the oral health intervention to standard care and tracks oral health, nutrition, quality of life, work ability, psychological well-being, and health costs. Data are collected through patient-reported outcomes, clinical dental assessments, and biological samples to understand the program’s impact. The trial is conducted across five Swedish regions, led by Uppsala University, with collaboration from regional health authorities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients (≥ 18 years)
* diagnosed with HNC
* scheduled for treatment with curative intent, including RT or CRT with or without surgery

Exclusion Criteria:

* severe alcoholism
* cognitive impairment
* inability to understand the Swedish language

Where it's running

• Uppsala University
  Uppsala, Sweden Recruiting

Study contacts

• Study coordinator: Ylva Tiblom Ehrsson, Assoc professor, RN
• Email: ylva.tiblom.ehrsson@uu.se
• Phone: +46707747712

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Induction therapy with toripalimab plus cisplatin and docetaxel for head and neck squamous cell carcinoma

  This study tests whether adding toripalimab to cisplatin and docetaxel induction therapy is safe and tolerable for adults with newly diagnosed locally advanced head and neck squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07214987

• Combination treatment for recurrent head and neck cancer

  This study is testing a new combination of two drugs, Surufatinib and Envolizumab, to see if they can help people with recurrent head and neck cancer feel better when other treatments haven't worked.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai · NCT06876844

• Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)

  This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.

  Recruiting Phase 2 Shaukat Khanum Memorial Cancer Hospital & Research Centre · Lahore, Punjab Province · NCT07919444

• Airway ultrasound in head and neck cancer patients

  This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.

  Recruiting at 2 sites University Hospital Dubrava · Zagreb, City of Zagreb and 1 other locations · NCT07910149

• Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia

  This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.

  Recruiting at 2 sites Phase 1 Rockefeller University · Minneapolis, Minnesota and 1 other locations · NCT07901959

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.